Design, Synthesis, and Evaluation of Putative B7-H3 Inhibitors for Group 3 Medulloblastoma

Medulloblastoma (MB) is the most common malignant brain tumor in children. Among its molecular subgroups, Group 3 MB (G3MB) is the most aggressive and linked to a high potential for metastasis, poor prognosis, and limited survival despite intensive multimodal therapy. Current treatments, which include maximal surgical removal followed by craniospinal irradiation (CSI) and chemotherapy, have improved outcomes; however, they often cause severe lifelong neurocognitive, endocrine, and psychological